ASX

Stonegate Initiates Coverage on Electro Optics Systems Holdings Ltd (EOS)

Retrieved on: 
Tuesday, May 30, 2023
EOS, Avista Capital Partners, ASX, Rare-earth element, Telescopic sight

Dallas, Texas--(Newsfile Corp. - May 30, 2023) - Electro Optics Systems Holdings Ltd (ASX: EOS): Stonegate Capital Partners initiates their coverage on Electro Optics Systems Holdings Ltd (ASX: EOS).

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - May 30, 2023) - Electro Optics Systems Holdings Ltd (ASX: EOS): Stonegate Capital Partners initiates their coverage on Electro Optics Systems Holdings Ltd (ASX: EOS).
  • The full report can be accessed by clicking on the following link: EOS.AX Initiation Report
    To view the full announcement, including downloadable images, bios, and more, click here .

EQS-News: EcoGraf Limited: POSCO Signs Cooperation Agreement

Retrieved on: 
Thursday, June 1, 2023
KRX, ASX, FSE, FMK, Sale, India–Singapore Comprehensive Economic Cooperation Agreement, EGR, Cooperation, POSCO International, OTCQX, POSCO, Electric battery, Aluminium

Diversified battery anode materials company EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to announce that it’s signed a non-binding Cooperation Agreement with POSCO International (“POSCO Intl”, KRX: 047050), a multinational industrial company headquartered in South Korea and a subsidiary of POSCO Holdings.

Key Points: 
  • Diversified battery anode materials company EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to announce that it’s signed a non-binding Cooperation Agreement with POSCO International (“POSCO Intl”, KRX: 047050), a multinational industrial company headquartered in South Korea and a subsidiary of POSCO Holdings.
  • The Cooperation Agreement follows a successful technical program between EcoGraf and POSCO Intl to assess EcoGraf’s graphite product performance and the on-going discussions between the parties about areas of collaboration to support the development of EcoGraf’s vertically integrated battery anode materials business.
  • EcoGraf will support POSCO Intl’s battery anode material requirements by supplying the following indicative volumes of product each year.
  • Locating EcoGraf™ battery anode material processing facilities near planned POSCO FUTURE M anode production developments to ensure logistical and operational efficiencies.

Xanadu Mines Results of 2023 Annual General Meeting

Retrieved on: 
Wednesday, May 31, 2023
Annual, TSX, Re Peveril Gold Mines Ltd, CTH, Annual general meeting, ASX, XAM, Corporation, Holding company

Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) advises that as required by ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the results of Xanadu Mines Ltd’s 2023 Annual General Meeting held as a Hybrid Meeting today, are set out in the attached report and includes a summary of the poll voting results and votes by proxies on the items of business considered at the Annual General Meeting.

Key Points: 
  • Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) advises that as required by ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the results of Xanadu Mines Ltd’s 2023 Annual General Meeting held as a Hybrid Meeting today, are set out in the attached report and includes a summary of the poll voting results and votes by proxies on the items of business considered at the Annual General Meeting.

Immuron Initiates Recruitment of Travelan® Clinical Study

Retrieved on: 
Tuesday, May 30, 2023
IMC, Institutional review board, US Foods, Enterotoxigenic Escherichia coli, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Diarrhea, Clinical trial, United States Army Medical Research and Development Command, Food and Drug Administration, ETEC, Gastroenteritis, ASX, Uniformed Services University of the Health Sciences, Trial of the century, IRB, Ethics, Ageing, FDA, Phase, CHIM, Food, Safety, Pharmaceutical industry, Immuron

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has received approval from the U.S. Army Medical Research and Development Command (USAMRDC) Office of Human and Animal Research Oversight (OHRO) to proceed with the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • The study has also been granted Institutional Review Board (IRB) human ethics and US Food and Drug Administration (FDA) approvals (ASX announcement December 23, 2022).
  • Immuron is now proceeding with the planned clinical trial in the United States and has initiated recruitment.
  • The clinical study will be conducted by Pharmaron CPC at its FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US.
  • This is one of four clinical trials Immuron has, or is soon to, initiate.

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Retrieved on: 
Tuesday, May 30, 2023
Multiple system atrophy, Pathology, Neuroimaging, Pharmacokinetics, ASX, Biomarker, MRI, ATH, Patient, MSA, SAN, Therapy, Safety, Disease, Pharmaceutical industry, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, May 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has commenced a new Phase 2 clinical trial of ATH434 in patients with Multiple System Atrophy (MSA) and the first patient has been enrolled. This open label study, entitled “A Biomarker Study of ATH434 in Participants with MSA” (ATH434-202) is in addition to the ongoing, randomized, double-blind, placebo-controlled Phase 2 trial in early-stage MSA (ATH434-201).

Key Points: 
  • This open label study, entitled “A Biomarker Study of ATH434 in Participants with MSA” (ATH434-202) is in addition to the ongoing, randomized, double-blind, placebo-controlled Phase 2 trial in early-stage MSA (ATH434-201).
  • The Biomarker trial will enroll approximately 15 individuals with more advanced MSA than those participating in the randomized trial.
  • “This Phase 2 Biomarker study complements our ongoing randomized Phase 2 trial, allowing us to evaluate the effect of ATH434 on two MSA populations of differing severity,” said David Stamler, M.D., Chief Executive Officer, Alterity.
  • Additional information on the open label Phase 2 trial can be found at clinicaltrials.gov NCT05864365.

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Retrieved on: 
Tuesday, May 30, 2023
IHL, Clarion, Benzodiazepine, California Institute for Regenerative Medicine, Johns Hopkins School of Medicine, California Institute of Integral Studies, Caffeine, Psychedelic drug, Johns Hopkins University, Patient, Principal, Psilocybin, Emergency medicine, GHB, Principal investigator, Research, Private practice, Certification, Terminal, Cocaine, Psychedelic therapy, The MINDS Foundation, Psychiatry, Cannabis, Addiction, MDA, DPT, NIH, PTSD, Depression, Sunstone, DSM-IV codes, LSD, Alcoholism, Advisory board, Ketamine, Johns Hopkins Center for Health Security, Behavioural sciences, Johns Hopkins, Economics, Yoga, Methamphetamine, ASX, Consciousness, Trust, CQD, Dextromethorphan, Medical director, Episode, MDMA, Pharmaceutical industry, Nursing

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.

Key Points: 
  • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
  • The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
  • Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
  • I’m grateful for their trust and support.”
    Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.

Patriot Battery Metals Appoints Vice President Project Development to its Executive Management Team

Retrieved on: 
Monday, May 29, 2023
Lithium, SNC-Lavalin, University, Project, BHP, Bachelor of Engineering, University of Technology Sydney, ASX, FSE, MBA, Mechanical, Business administration, Master of Business Administration, Electricity, Engineering

VANCOUVER, British Columbia and SYDNEY, Australia, May 29, 2023 (GLOBE NEWSWIRE) -- Patriot Battery Metals Inc. (the “Company” or “Patriot”) (TSX-V: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce the appointment of Greg Barfoot, BEng, Meng, MBA to the position of Vice President Project Development.

Key Points: 
  • VANCOUVER, British Columbia and SYDNEY, Australia, May 29, 2023 (GLOBE NEWSWIRE) -- Patriot Battery Metals Inc. (the “Company” or “Patriot”) (TSX-V: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce the appointment of Greg Barfoot, BEng, Meng, MBA to the position of Vice President Project Development.
  • “I am very pleased to welcome Greg to the Patriot team.
  • Our team is growing as we start heading down the development pathway for the CV5 Project.
  • Over the past 25 years Mr. Barfoot has held senior project development roles with BHP, SNC Lavalin and Fluor.

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

Retrieved on: 
Monday, May 29, 2023
GLP, Human, Drug development, Cancer, IL-6, ASX, Toxicity, Immunotherapy, River, IMM, DSM-IV codes, Autoimmune disease, Immutep, Drug discovery, Cytokine, IND, Safety, Pharmaceutical industry, Vaccine, LAG-3

SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with Charles River under which Charles River will conduct a GLP toxicology study for IMP761, Immutep's proprietary preclinical candidate for autoimmune diseases. IMP761 is a first-in-class LAG-3 agonist antibody that aims to address the underlying cause of many autoimmune diseases, namely the overactivation of self-antigen-specific memory T cells expressing LAG-3.

Key Points: 
  • Charles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across more than 20 countries
    SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with Charles River under which Charles River will conduct a GLP toxicology study for IMP761, Immutep's proprietary preclinical candidate for autoimmune diseases.
  • Preclinical toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested in humans.
  • With its well-established expertise assisting companies in early-stage drug development, Charles River is the partner of choice to help progress our IMP761 program through this key stage of IND-enabling studies.
  • The GLP (Good Laboratory Practice) toxicology results and other preclinical studies will be an essential part of the Company’s clinical trial application for IMP761.

University of Oklahoma Joins the BrainChip University AI Accelerator Program

Retrieved on: 
Wednesday, May 31, 2023
Education, Semiconductor, Technology, Software, Artificial Intelligence, University, Hardware, Radar, Learning, Specialization, Weather radar, Student, ADR, University of Oklahoma, Teaching, Internet of things, Ecosystem, Rochester Institute of Technology, ASX, Low-code development platform, Research, Computer, Associate, OU, Carnegie Mellon University, Weather, BrainChip, Arizona State University, School, OTCQX, National Weather Service Training Center, Watt, National Weather Service, Electricity, Purdue University School of Electrical and Computer Engineering, Medical device, Nursing

BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, today announced that University of Oklahoma (OU) has joined the University AI Accelerator Program to ensure students have the tools and resources needed to encourage development of cutting-edge technologies that will continue to usher in an era of essential AI solutions.

Key Points: 
  • BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, today announced that University of Oklahoma (OU) has joined the University AI Accelerator Program to ensure students have the tools and resources needed to encourage development of cutting-edge technologies that will continue to usher in an era of essential AI solutions.
  • BrainChip’s University AI Accelerator Program provides hardware, training, and guidance to students at higher education institutions with existing AI engineering programs.
  • With Oklahoma being the home of the National Weather Service, this skill set will be especially important in applying sustainable and efficient AI to this increasingly important sector.”
    OU joins current participants Arizona State University, Carnegie Mellon University and Rochester Institute of Technology in the accelerator program.
  • Other institutions of higher education interested in how they can become members of BrainChip’s University AI Accelerator Program can find more details at https://brainchip.com/brainchip-university-ai-accelerator/ .

ASE VIPack™ FOCoS-Bridge integrates multiple ASICs and silicon bridges to accelerate AI innovation

Retrieved on: 
Wednesday, May 31, 2023
Data Management, Consumer Electronics, Technology, Manufacturing, Public Relations, Investor Relations, Communications, Semiconductor, Software, Artificial Intelligence, Engineering, Hardware, Application-specific integrated circuit, HBM, Communication, R&D, Sales & Marketing Executives International, Deep learning, ASX, UCIe, Creativity, BOW, AIB, HPC, Algorithm, Socs, ASE, Artificial intelligence, High Bandwidth Memory, D2D, Silicon, Memory, NYSE, ASIC, Computer data storage, Medical device, TAIEX, AI

FOCoS-Bridge technology addresses the increasing demand for higher bandwidth and faster data transfer rates in AI and HPC applications.

Key Points: 
  • FOCoS-Bridge technology addresses the increasing demand for higher bandwidth and faster data transfer rates in AI and HPC applications.
  • ASE’s FOCoS-Bridge features ultra-high density D2D interconnection with submicron L/S, enabling high bandwidth at low latency for chiplet integration.
  • The use of a silicon bridge die enables a die edge linear density (wire/mm/layer) that is nearly 200x higher than the traditional organic flip chip package.
  • The convergence of AI and HPC is having a strong impact on the semiconductor industry, fueling demand for innovative packaging solutions.